アンチセンスとRNAi治療薬市場：技術、投与経路、用途、エンドユーザー別-2025-2030年の世界予測

アンチセンスとRNAi治療薬市場は、2023年に44億3,000万米ドルと評価され、2024年には50億7,000万米ドルに達すると予測され、CAGR 14.64％で成長し、2030年には115億4,000万米ドルに達すると予測されています。

アンチセンスおよびRNA干渉（RNAi）治療薬は、遺伝子発現調節に焦点を当てたバイオ医薬品の画期的な分野です。特定の遺伝子をオフにすることで、これらの治療法は様々な疾患、特に遺伝性疾患、がん、神経疾患への応用が期待されています。これらの治療法の必要性は、従来の治療法では不十分な希少遺伝性疾患の治療など、アンメットニーズから生じています。主な最終用途には、臨床研究、病院での治療、専門クリニックなどがあり、そこでは標的遺伝子治療がより正確な治療選択肢を提供しています。市場の成長には、ゲノム研究への投資の増加、RNAベースの治療薬の技術的進歩、遺伝性疾患の有病率の上昇などの要因があります。また、規制当局の支援や主要バイオテクノロジー企業間の提携も勢いを増しています。主なビジネスチャンスは、RNAiプラットフォームの多様化と、肝臓や眼球への投与だけでなく、広範な組織への投与を含めた治療ターゲットの拡大にあります。しかし、高い開発コスト、厳しい規制要件、オフターゲット効果や免疫反応のような送達メカニズムにおける課題などの要因により、成長は抑制されています。こうした制約から、治療効果と安全性を高めるために、革新的な送達システムと合成生物学の進歩が必要となります。この分野でのイノベーションは、AIと機械学習の統合による遺伝子ターゲットの予測精度の向上と設計の特異性の改善に資する可能性があります。強固な研究開発パイプライン、戦略的パートナーシップ、独自のRNAiプラットフォームのためのIP開発に投資する企業にとって、事業成長の可能性はかなり大きいです。急速な技術シフトと激しい市場競争を特徴とする市場のダイナミックな性質により、新たな科学的発展への機敏な適応と対応が求められます。今後の研究は、デリバリー手段の最適化と治療指標の拡大に重点を置き、長期的な持続可能性と市場での成功を高めるべきです。企業はまた、規制状況の変化を積極的に監視して、戦略を調整し、市場の加速を効果的に活用すべきです。

市場力学：急速に進化するアンチセンスとRNAi治療薬市場の主要市場インサイトを公開

アンチセンスとRNAi治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の遺伝性疾患の有病率の増加
  • アンチセンスおよびRNAiベースの治療に関する研究開発活動の活発化
• 市場抑制要因
  • アンチセンス・RNAi治療薬の製造コストの高さ
• 市場機会
  • バイオテクノロジー企業と学術機関の共同研究が加速
  • 個別化医療に対する意識の高まり
• 市場の課題
  • アンチセンスRNAi治療薬の有効性に関する懸念

ポーターのファイブフォース：アンチセンスとRNAi治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：アンチセンスとRNAi治療薬市場における外部からの影響の把握

外部マクロ環境要因は、アンチセンスとRNAi治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析アンチセンスとRNAi治療薬市場における競合情勢の把握

アンチセンスとRNAi治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスアンチセンスとRNAi治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、アンチセンスとRNAi治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨アンチセンスとRNAi治療薬市場における成功への道筋を描く

アンチセンスとRNAi治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で遺伝性疾患の罹患率が増加
    • アンチセンスおよびRNAiベースの治療法に関する研究開発活動の増加
  • 抑制要因
    • アンチセンスRNAi治療薬の製造コストが高い
  • 機会
    • バイオテクノロジー企業と学術機関の連携が加速し、アンチセンスとRNAi治療薬調査を推進
    • 個別化医療に対する意識の高まり
  • 課題
    • アンチセンスRNAi治療薬の有効性に関する懸念
• 市場セグメンテーション分析
  • テクノロジー：正確な遺伝子ターゲティングによるRNA干渉の採用増加
  • 応用：がん特異的変異を標的とすることで、腫瘍学におけるアンチセンスとRNAi治療薬の応用を促進
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 アンチセンスとRNAi治療薬市場：技術別

• アンチセンスRNA
• RNA干渉
  • マイクロRNA
  • siRNA

第7章 アンチセンスとRNAi治療薬市場：投与経路別

• 皮内注射
• 腹腔内注射
• 静脈注射
• 肺への送達
• 局所的送達

第8章 アンチセンスとRNAi治療薬市場：用途別

• 心血管疾患（CVD）
• 遺伝性疾患
• 感染症
• 神経変性疾患
• 腫瘍学
• 腎臓疾患
• 呼吸器疾患

第9章 アンチセンスとRNAi治療薬市場：エンドユーザー別

第9章 2.病院：

• 製薬・バイオテクノロジー企業
• 調査・学術機関
• 専門クリニック

第10章 南北アメリカのアンチセンスとRNAi治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のアンチセンスとRNAi治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのアンチセンスとRNAi治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • シルナオミクス社はボストンで開催された2024 OPT会議で革新的なgalAhead muRNA技術を展示しました。
  • リボキュア・ファーマシューティカルズABとベーリンガーインゲルハイム・インターナショナルGmbHが革新的なRNAiベースの治療法の開発で提携
  • 上海アルゴバイオファーマシューティカル株式会社は、ノバルティスAGと提携し、心血管疾患のRNAi治療薬の開発に向けて41億6,500万米ドルの画期的な契約を締結しました。
• 戦略分析と提言

企業一覧

• Alnylam Pharmaceuticals, Inc.
• Amarna Therapeutics BV
• Arbutus Biopharma Corporation
• Arrowhead Pharmaceuticals, Inc.
• AstraZeneca plc
• Benitec Biopharma Limited
• Carisma Therapeutics Inc.
• Evox Therapeutics Ltd
• GenScript Biotech Corporation
• Ionis Pharmaceuticals, Inc.
• Novo Nordisk A/S
• Regenxbio Inc.
• Sanofi S.A.
• Silence Therapeutics plc
• Sirnaomics, Inc.
• Viridian Therapeutics, Inc.
• Wave Life Sciences Ltd

LIST OF FIGURES

• FIGURE 1. ANTISENSE & RNAI THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTISENSE & RNAI THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTISENSE & RNAI THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE RNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MIRNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRA-DERMAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAPERITONEAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PULMONARY DELIVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES (CVDS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RENAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY HOSPITALS:, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 50. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 77. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 81. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 82. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 167. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 168. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 187. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 188. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 191. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 192. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 193. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 241. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 242. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Antisense & RNAi Therapeutics Market was valued at USD 4.43 billion in 2023, expected to reach USD 5.07 billion in 2024, and is projected to grow at a CAGR of 14.64%, to USD 11.54 billion by 2030.

Antisense and RNA interference (RNAi) therapeutics represent a groundbreaking segment in biopharmaceuticals focused on gene expression modulation. By turning off specific genes, these therapies offer promising applications across various diseases, particularly genetic disorders, cancers, and neurological conditions. The necessity of these therapies arises from unmet clinical needs, such as treating rare genetic maladies for which traditional therapies fall short. Key end-use applications include clinical research, hospital treatments, and specialty clinics, where targeted gene therapy offers more precise treatment options. Market growth is fueled by factors such as increased investment in genomic research, technological advancements in RNA-based therapeutics, and a rising prevalence of genetic disorders. Regulatory support and collaborations among key biotech companies also add momentum. Major opportunities lie in diversifying RNAi platforms and expanding therapeutic targeting beyond liver and ocular delivery to include widespread tissue distribution. However, growth is restrained by factors like high development costs, stringent regulatory requirements, and challenges in delivery mechanisms like off-target effects and immune responses. These constraints necessitate innovative delivery systems and synthetic biology advancements to enhance therapeutic efficacy and safety. Innovation in this arena could capitalize on the integration of AI and machine learning to better predict gene targets and improve design specificity. The business growth potential is considerable for companies investing in robust R&D pipelines, strategic partnerships, and IP development for proprietary RNAi platforms. The dynamic nature of the market, characterized by rapid technological shifts and intensive competition, demands nimble adaptation and responsiveness to emerging scientific developments. Future research should focus on optimizing delivery vehicles and expanding the therapeutic index, enhancing long-term sustainability and marketable success. Businesses should also actively monitor changes in regulatory landscapes to adjust strategies and leverage market acceleration effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antisense & RNAi Therapeutics Market

The Antisense & RNAi Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of genetic disorders worldwide
  • Rise in R&D activities on antisense and RNAi-based therapies
• Market Restraints
  • High cost of manufacturing antisense-RNAi-therapeutics
• Market Opportunities
  • Collaboration between biotech companies and academic institutions accelerates for antisense & RNAi therapeutics research
  • Rising awareness about personalized medicine
• Market Challenges
  • Concerns associated with the efficacy of antisense-RNAi-therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Antisense & RNAi Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antisense & RNAi Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antisense & RNAi Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antisense & RNAi Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antisense & RNAi Therapeutics Market

A detailed market share analysis in the Antisense & RNAi Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antisense & RNAi Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antisense & RNAi Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antisense & RNAi Therapeutics Market

A strategic analysis of the Antisense & RNAi Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antisense & RNAi Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amarna Therapeutics BV, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Benitec Biopharma Limited, Carisma Therapeutics Inc., Evox Therapeutics Ltd, GenScript Biotech Corporation, Ionis Pharmaceuticals, Inc., Novo Nordisk A/S, Regenxbio Inc., Sanofi S.A., Silence Therapeutics plc, Sirnaomics, Inc., Viridian Therapeutics, Inc., and Wave Life Sciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Antisense & RNAi Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Antisense RNA and RNA Interference. The RNA Interference is further studied across miRNA and siRNA.
• Based on Route of Administration, market is studied across Intra-dermal Injections, Intraperitoneal Injections, Intravenous Injections, Pulmonary Delivery, and Topical Delivery.
• Based on Application, market is studied across Cardiovascular Diseases (CVDs), Genetic Disorders, Infectious Diseases, Neurodegenerative Disorders, Oncology, Renal Diseases, and Respiratory Disorders.
• Based on End User, market is studied across Hospitals:, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of genetic disorders worldwide
    • 5.1.1.2. Rise in R&D activities on antisense and RNAi-based therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of manufacturing antisense-RNAi-therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaboration between biotech companies and academic institutions accelerates for antisense & RNAi therapeutics research
    • 5.1.3.2. Rising awareness about personalized medicine
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with the efficacy of antisense-RNAi-therapeutics
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: increasing adoption of RNA interference owing to precise genetic targeting
  • 5.2.2. Application: Boosting applications of antisense & RNAi therapeutics in oncology due to targeting cancer-specific mutations
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antisense & RNAi Therapeutics Market, by Technology

• 6.1. Introduction
• 6.2. Antisense RNA
• 6.3. RNA Interference
  • 6.3.1. miRNA
  • 6.3.2. siRNA

7. Antisense & RNAi Therapeutics Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intra-dermal Injections
• 7.3. Intraperitoneal Injections
• 7.4. Intravenous Injections
• 7.5. Pulmonary Delivery
• 7.6. Topical Delivery

8. Antisense & RNAi Therapeutics Market, by Application

• 8.1. Introduction
• 8.2. Cardiovascular Diseases (CVDs)
• 8.3. Genetic Disorders
• 8.4. Infectious Diseases
• 8.5. Neurodegenerative Disorders
• 8.6. Oncology
• 8.7. Renal Diseases
• 8.8. Respiratory Disorders

9. Antisense & RNAi Therapeutics Market, by End User

• 9.1. Introduction

9.2. Hospitals:

• 9.3. Pharmaceutical & Biotechnology Companies
• 9.4. Research & Academic Institutes
• 9.5. Specialty Clinics

10. Americas Antisense & RNAi Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Antisense & RNAi Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Antisense & RNAi Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Sirnaomics Ltd. showcased innovative galAhead muRNA technology at the 2024 OPT congress in Boston
  • 13.3.2. Ribocure Pharmaceuticals AB and Boehringer Ingelheim International GmbH partner to develop innovative RNAi-based treatments
  • 13.3.3. Shanghai Argo Biopharmaceutical Co., Ltd. partnered with Novartis AG in a Landmark USD 4.165 Billion deal to advance RNAi therapeutics for cardiovascular diseases
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alnylam Pharmaceuticals, Inc.
• 2. Amarna Therapeutics BV
• 3. Arbutus Biopharma Corporation
• 4. Arrowhead Pharmaceuticals, Inc.
• 5. AstraZeneca plc
• 6. Benitec Biopharma Limited
• 7. Carisma Therapeutics Inc.
• 8. Evox Therapeutics Ltd
• 9. GenScript Biotech Corporation
• 10. Ionis Pharmaceuticals, Inc.
• 11. Novo Nordisk A/S
• 12. Regenxbio Inc.
• 13. Sanofi S.A.
• 14. Silence Therapeutics plc
• 15. Sirnaomics, Inc.
• 16. Viridian Therapeutics, Inc.
• 17. Wave Life Sciences Ltd